| Randomized Phase III Study of EGFR Tyrosine Kinase Inhibitor and Intercalated Platinum-Doublet Chemotherapy for Non-Small Cell Lung Cancer Harboring EGFR Mutation.PMID 40162917 · Clin Cancer Res |
2025-Jun-13 |
1 | 3 | 3 | 6 |
提取完成 |
| The MURANO study: final analysis and retreatment/crossover substudy results of VenR for patients with relapsed/refractory CLL.PMID 40009494 · Blood |
2025-Jun-05 |
5 | 9 | 9 | 18 |
提取完成 |
| Pegylated liposomal doxorubicin + cyclophosphamide followed by taxane as adjuvant therapy for early-stage breast cancer: a randomized controlled trial.PMID 40504550 · Oncologist |
2025-Jun-04 |
1 | 2 | 2 | 4 |
提取完成 |
| Prognostic relation of body mass index on extended aromatase inhibition treatment in postmenopausal patients with estrogen receptor positive breast cancer: A retrospective analysis of the SOLE trial.PMID 40286474 · Eur J Cancer |
2025-Jun-03 |
1 | 6 | 5 | 11 |
部分完成 |
| Prognostic and predictive analyses of circulating plasma biomarkers in men with metastatic castration resistant prostate cancer treated with docetaxel/prednisone with or without bevacizumab.PMID 38347114 · Prostate Cancer Prostatic Dis |
2025-Jun |
1 | 1 | 1 | 3 |
质量警告 |
| Olaparib Plus Abiraterone in Asian Patients With Metastatic Castration-Resistant Prostate Cancer: PROpel Subset Analysis.PMID 40099663 · Cancer Sci |
2025-Jun |
3 | 3 | 3 | 6 |
提取完成 |
| Transarterial chemoembolization plus apatinib for unresectable hepatocellular carcinoma: a multicenter, randomized, open-label, phase III trial.PMID 40437469 · BMC Med |
2025-May-28 |
1 | 1 | 0 | 0 |
提取失败 |
| High-Dose Methotrexate in Children and Young Adults With ALL and Lymphoblastic Lymphoma: Results of the Randomized Phase III Study UKALL 2011.PMID 40193822 · J Clin Oncol |
2025-May-20 |
1 | 3 | 3 | 3 |
提取完成 |
| Neoadjuvant PARP inhibitor scheduling in BRCA1 and BRCA2 related breast cancer: PARTNER, a randomized phase II/III trial.PMID 40360463 · Nat Commun |
2025-May-13 |
1 | 6 | 6 | 14 |
提取完成 |
| Pertuzumab Retreatment for Human Epidermal Growth Factor Receptor 2-Positive Locally Advanced/Metastatic Breast Cancer (PRECIOUS Study): Final Overall Survival Analysis.PMID 39854662 · J Clin Oncol |
2025-May-10 |
2 | 3 | 3 | 6 |
提取完成 |
| Pembrolizumab Plus Docetaxel Versus Docetaxel for Previously Treated Metastatic Castration-Resistant Prostate Cancer: The Randomized, Double-Blind, Phase III KEYNOTE-921 Trial.PMID 40043230 · J Clin Oncol |
2025-May-10 |
2 | 2 | 2 | 4 |
提取完成 |
| Capivasertib plus fulvestrant in patients with HR-positive/HER2-negative advanced breast cancer: phase 3 CAPItello-291 study extended Chinese cohort.PMID 40346047 · Nat Commun |
2025-May-09 |
2 | 4 | 4 | 8 |
提取完成 |
| Patient-reported outcomes from DESTINY-Breast04: trastuzumab deruxtecan versus physician's choice of chemotherapy in patients with HER2-low mBC.PMID 40349139 · Oncologist |
2025-May-08 |
1 | 3 | 3 | 4 |
质量警告 |
| First-line treatment of anti-EGFR monoclonal antibody cetuximab β plus FOLFIRI versus FOLFIRI alone in Chinese patients with RAS/BRAF wild-type metastatic colorectal cancer: a randomized, phase 3 trial.PMID 40328753 · Signal Transduct Target Ther |
2025-May-07 |
1 | 2 | 2 | 2 |
质量警告 |
| Fulvestrant Versus Anastrozole in Endocrine Therapy-Naïve Women With Hormone Receptor-Positive Advanced Breast Cancer: Final Overall Survival in the Phase III FALCON Trial.PMID 39772884 · J Clin Oncol |
2025-May |
2 | 5 | 5 | 10 |
提取完成 |
| First-Line Mobocertinib Versus Platinum-Based Chemotherapy in Patients With EGFR Exon 20 Insertion-Positive Metastatic Non-Small Cell Lung Cancer in the Phase III EXCLAIM-2 Trial.PMID 39879577 · J Clin Oncol |
2025-May |
2 | 4 | 4 | 8 |
提取完成 |
| Pembrolizumab plus chemotherapy in advanced or recurrent endometrial cancer: overall survival and exploratory analyses of the NRG GY018 phase 3 randomized trial.PMID 40044930 · Nat Med |
2025-May |
2 | 4 | 4 | 8 |
提取完成 |
| Neoadjuvant Nivolumab Plus Ipilimumab Versus Chemotherapy in Resectable Lung Cancer.PMID 39778121 · J Clin Oncol |
2025-Apr-20 |
1 | 2 | 2 | 4 |
提取完成 |
| Metronomic Capecitabine Plus Aromatase Inhibitor as Initial Therapy in Patients With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: The Phase III MECCA Trial.PMID 39746176 · J Clin Oncol |
2025-Apr-10 |
3 | 3 | 3 | 6 |
提取完成 |
| Trastuzumab-Pertuzumab Plus Eribulin or Taxane as First-Line Chemotherapy for Human Epidermal Growth Factor 2-Positive Locally Advanced/Metastatic Breast Cancer: The Randomized Noninferiority Phase III EMERALD Trial.PMID 39787453 · J Clin Oncol |
2025-Apr-10 |
3 | 3 | 3 | 6 |
提取完成 |
| Bireociclib plus fulvestrant for HR+/HER2- advanced female breast cancer progressed on or after endocrine therapy: phase 3 BRIGHT-2 study interim analysis.PMID 40204778 · Nat Commun |
2025-Apr-09 |
1 | 2 | 2 | 4 |
提取完成 |
| Pancreatic Adenocarcinoma: Long-Term Outcomes of Adjuvant Therapy in the ESPAC4 Phase III Trial.PMID 39637340 · J Clin Oncol |
2025-Apr |
1 | 2 | 2 | 6 |
提取完成 |
| Biomarker analyses from the phase III randomized CLEAR trial: lenvatinib plus pembrolizumab versus sunitinib in advanced renal cell carcinoma.PMID 39672382 · Ann Oncol |
2025-Apr |
1 | 10 | 10 | 18 |
质量警告 |
| Avelumab + axitinib versus sunitinib as first-line treatment for patients with advanced renal cell carcinoma: final analysis of the phase III JAVELIN Renal 101 trial.PMID 39706335 · Ann Oncol |
2025-Apr |
1 | 2 | 2 | 4 |
提取完成 |
| Daratumumab plus bortezomib, lenalidomide and dexamethasone for transplant-ineligible or transplant-deferred newly diagnosed multiple myeloma: the randomized phase 3 CEPHEUS trial.PMID 39910273 · Nat Med |
2025-Apr |
1 | 2 | 2 | 3 |
质量警告 |
| Updated efficacy and safety of HLX02 versus reference trastuzumab in metastatic HER2-positive breast cancer: A randomized phase III equivalence trial.PMID 39954568 · Breast |
2025-Apr |
1 | 2 | 2 | 4 |
提取完成 |
| A randomized phase II/III study of paclitaxel/carboplatin/metformin versus paclitaxel/carboplatin/placebo as initial therapy for measurable stage III or IVA, stage IVB, or recurrent endometrial cancer: An NRG oncology/GOG study.PMID 40056832 · Gynecol Oncol |
2025-Apr |
2 | 4 | 4 | 7 |
质量警告 |
| Incorporation of triapine (T) to cisplatin chemoradiation (CRT) for locally advanced cervical and vaginal cancer: Results from NRG-GY006, a phase III randomized trial.PMID 40101606 · Gynecol Oncol |
2025-Apr |
1 | 1 | 1 | 2 |
提取完成 |
| Avelumab first-line maintenance for advanced urothelial carcinoma: long-term outcomes from the JAVELIN Bladder 100 trial in older patients.PMID 40107155 · ESMO Open |
2025-Apr |
1 | 2 | 2 | 6 |
提取完成 |
| Abemaciclib Plus Fulvestrant in Advanced Breast Cancer After Progression on CDK4/6 Inhibition: Results From the Phase III postMONARCH Trial.PMID 39693591 · J Clin Oncol |
2025-Mar-20 |
3 | 11 | 11 | 22 |
提取完成 |